Skip to Content


Join Us     Home    About The Site    Glossary    

 

Print a PDF of this page

Download PDF reader

Book Icon = glossary definition Print a PDF of this page. Download PDF Reader


Marfan Study Basics

Marfan is a Trial of Beta Blocker (BB) Therapy (Atenolol) vs. Angiotensin II Receptor Blocker (ARB) Therapy (Losartan) in Individuals with Marfan Syndrome (MFS). The target number of participants is 604. The accrual period is approximately 6 years with recruitment to begin in the Fall of 2006.

Study Design

A Phase III, randomized Book Icon , double-blind, multi-center trial to compare the effect of BB therapy to that of ARB therapy on rates of aortic growth and progression of aortic regurgitation in individuals with MFS. Patients are followed for three years after randomization.

Primary Endpoint

Rate of change in aortic root body surface area adjusted Z-score.

Secondary Endpoints

  1. Frequency of combined endpoint: aortic dissection, aortic root surgery or death
  2. Rate of change of mitral regurgitation
  3. Rate of progression of left ventricular dilation and dysfunction
  4. Rate of change in central aortic stiffness indices
  5. Long bone overgrowth and weight gain
  6. Comparison of adverse drug reactions between groups

Inclusion Criteria

  1. 6 months to 25 years of age
  2. Diagnosis of MFS according to Ghent criteria
  3. Aortic root Z-score >3.0

Exclusion Criteria

  1. Prior aortic surgery
  2. Aortic root dimension at the sinuses of Valsalva >5 cm.
  3. Planned aortic surgery within 6 months of enrollment
  4. Aortic dissection
  5. Shprintzen-Goldberg syndrome
  6. Loeys-Dietz syndrome
  7. Therapeutic rather than prophylactic use of ACE-I, BB, or calcium channel blocker (e.g. for arrhythmia, ventricular dysfunction or valve regurgitation)
  8. History of angioedema while taking ACE-I or BB
  9. Intolerance to losartan or other ARB that resulted in termination of therapy
  10. Intolerance to atenolol or other BB that resulted in termination of therapy
  11. Renal dysfunction
  12. Asthma of sufficient severity to preclude use of a BB
  13. Diabetes mellitus
  14. Pregnancy or planned pregnancy within 36 months of enrollment
  15. Inability to complete study procedures including history of poor acoustic windows (inability to obtain accurate measurement of aortic root)
Study Basics Study Design Primary Endpoint Secondary Endpoint Inclusion Criteria Exclusion Criteria
B2B logo    Children and Clinical Studies logo
Please disable any pop-up blockers to take full advantage of all of the features of this website.
Pediatric Heart Network Department of Health and Human Services Link National Institutes of Health Link